Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
672 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01221506 | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) | completed | Early Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT04040712 |
| Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors |
| completed |
| N/A |
| 20 |
| Catholic University of the Sacred HeartOTHER |
| 1 |
| Mar 17, 2020 |
| clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02406521 | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02700659 | The Cxbladder Monitoring Study | completed | — | 803 | Pacific Edge LimitedINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT04295174 | KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers | completed | — | 70 | Odense University HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02014636 | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) | completed | Phase 1 | 42 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 3, 2020 | clinicaltrials |
| NCT00749320 | Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) | completed | N/A | 32 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT02645409 | Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma | completed | N/A | 14 | Chandru SundaramOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02325921 | MRI in Renal Tumors | completed | — | 39 | Radboud University Medical CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01846520 | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | completed | N/A | 200 | City of Hope Medical CenterOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01550367 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | completed | Phase 1 / Phase 2 | 30 | Leonard ApplemanOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04213157 | Laparoscopic Partial Nephrectomy for cT1 Tumors | completed | — | 292 | Samsun Liv HospitalOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT00304460 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | completed | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00106301 | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | completed | Phase 2 | 2 | CelgeneINDUSTRY | 2 | Nov 18, 2019 | clinicaltrials |
| NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00923169 | Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT02187042 | Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line(RENACALL) | completed | — | 70 | PfizerINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02700568 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors(FavorAx) | completed | Phase 2 | 21 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02864615 | Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy | completed | N/A | 17 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03379012 | Testosterone in Metastatic Renal Cell Carcinoma Patients(FARETES) | completed | Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00106613 | A Research Study for Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03519542 | Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma(SOGANG) | completed | — | 62 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02843607 | Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT02351739 | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer(KEYNOTE143) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01282463 | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma | completed | Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2019 | clinicaltrials |
| NCT03699579 | Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC | completed | — | 28 | IpsenINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03507166 | A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01339975 | Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma(ChemoRenCan) | completed | — | 310 | University Hospital, BordeauxOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT02300610 | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | completed | Phase 1 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02315755 | Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC | completed | — | 102 | PfizerINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT03744585 | Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.(CABOREAL) | completed | — | 450 | IpsenINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT00005851 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT01026337 | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | completed | — | 43 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT01206764 | A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. | completed | Phase 4 | 143 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 24, 2019 | clinicaltrials |
| NCT01415167 | PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy | completed | — | 1,690 | Prometheus LaboratoriesINDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 26, 2020source: clinicaltrials